Qrons Profile
Qrons Inc. operates as a biotechnology company.
The company is dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. The company's approach is to marshal and leverage the company's proprietary research with developing breakthrough technologies in the fields of artificial intelligence ('AI'), machine learning ('ML'), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. To accomplish this, the company seeks to engage in strategic arrangements with companies and institutions. The company's search is focused on researchers based in Israel.
As of December 31, 2022, the company had collaborated with universities and scientists in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels to develop a treatment that integrates proprietary, engineered mesenchymal stem cells ('MSCs'), 3D printable implant, smart materials and a novel delivery system. The company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries ('TBIs'), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100 is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200 is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.
In early 2022, the company began collaborating with scientists at a leading University in Israel to conduct preliminary experiments to confirm that a combination of certain molecule compounds that they invented which contain immunomodulating properties when integrated with ingredients in the company's QS200 product candidate may substantially improve its solubility and allow very high dosage treatments, which offers treatment options to diffused axonal injuries. These molecules are being tested for certain indication in various Phase II trials conducted by others.
The company is looking to conduct such in vitro tests, which if successful the company may provide an expedited pathway to human trials.
Under an intellectual property license agreement (the 'Intellectual Property Agreement') with the Trustees of Dartmouth College ('Dartmouth') to develop innovative 3D printable, biocompatible advanced materials, Dartmouth granted the company an exclusive worldwide, royalty bearing license for 3D printable materials in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services.
The company developed two product candidates, QS100 for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries. Both QS100 and QS200 integrate proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs and smart synthetic material. QS100 is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel to treat penetrating brain injuries (such as gunshot wounds, motor vehicle accidents and falls) and QS200 is an injectable MSCs-synthetic hydrogel for the treatment of diffused axonal injuries.
QS100 has demonstrated astrogliosis inhibition and induction of neuronal differentiation in the company's in-vivo animal experiment penetrating injury animal model. QS200 research has shown efficacy for concussions and diffused brain injuries.
QS100TM's advances provide a superior stem cells/synthetic hydrogel integration which will enable the unleashing of a precise, effective and controlled delivery of the company's proprietary MSCs so as to induce neuronal growth.
QS200 may substantially improve solubility of certain molecules that have been identified and allow very high dosage treatments, which offers treatment options to diffused axonal injuries.
Building on the company's activities in its research activities for TBI's and its activities and interactions in Israel, the company has expanded its proprietary TBI research, to create a platform making use of synergic technologies to combat a broader range of additional neuronal diseases.
The company's intention is to develop and license biotech products, treatments and technologies through the creation of a platform to combat neuronal diseases. The company's approach is to seek to marshal and leverage the remarkable advances made in the fields of AI, ML, molecular biology, stem cells and tissue engineering for deployment in the fight against neuronal diseases. The company seeks to accomplish this through development, acquisitions and investments.
The company is seeking to engage in strategic and partner arrangements and provide assistance and support in furtherance of the company's development goals. The company seeks companies and institutions that are developing breakthrough technologies in line with the company's approach. The company's search is focused on researchers based in Israel.
The company has identified at least two other product candidates and subject to funding intend to initiate invitro testing.
Intellectual Property
Dartmouth granted the company an exclusive worldwide, royalty bearing license for such 3D printable materials in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services pursuant to the Intellectual Property Agreement.
On April 9, 2018, the company filed a provisional patent application with the USPTO entitled 'Techniques for Promoting Neuronal Recovery' and on January 22, 2019, filed a second application that included further technological developments and data. In addition, on April 7, 2019, the company filed a Patent Cooperation Treaty ('PCT') application with the World Intellectual Property Organization to allow the company to file patent applications and seek protection in most major market countries throughout the world. On September 23, 2020, the company filed with the USPTO the U.S. National Phase of its international PCT application thereby initiating its application for a United States Patent.
On April 3, 2022, the company filed a provisional patent application with the USPTO entitled Therapeutic Polypseudorotaxane Hydrogels'. The patent relates generally to the treatment of pathological central nervous system conditions, such as traumatic injury or neurodegenerative disease. More specifically some applications of the invention relate to uses of hydrogels in the treatment of such conditions. Further, the company has filed an International Patent Application at the International Bureau, for the inventions of Therapeutic Polypseudorotaxane Hydrogels in order to provide the company with the option to, in the future, seek protection for these inventions globally. This International Patent Application was filed on March 12, 2023, and was assigned application number PCT/IB2023/052368.
Subject to sufficient resources the company plans to file several additional patents relating to the integration of its QS200 with certain molecules to treat sepsis and separately to treat diffused axonal injuries.
On November 15, 2017, Dartmouth filed a utility patent application with the USPTO for 'Mechanically Interlocked Molecules-Based Materials' for 3-D printing, which the company financed by reimbursing Dartmouth for patent filing costs.
The company's strategy of creating a platform through development, acquisition and investment is to enable it to obtain access to patented intellectual property in a more streamlined and cost-effective fashion as the patent process will have either been already granted or be at a later stage in the application process.
Agreements with Dartmouth
On October 2, 2019, the company entered into the Intellectual Property Agreement pursuant to which Dartmouth granted the company an exclusive world-wide license under the patent application entitled 'Mechanically Interlocked Molecules-based Materials for 3D Printing' in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the company to sublicense to third parties subject to the terms of the Agreement.
Research and Development
During the year ended December 31, 2022, the company incurred research and development costs of $194,406.
History
The company was founded in 2016. It was incorporated under the laws of the state of Wyoming in 2016. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in 2017.
